At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 962 enrolled
Drug / intervention
Rimegepant +1 moredrug
Likely dose
Rimegepant 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications
In Brief
A Phase 4 clinical trial evaluating Rimegepant and Placebo for Migraine. Completed, enrolled 962 participants across 111 sites in 14 countries.
Detailed Summary
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesAustralia, Austria, Belgium, Canada, Denmark, Finland, Germany, Italy, Mexico, Poland, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartNov 2022
Primary CompletionMar 2025
Study CompletionJul 2025
TodayJul 2026
First PostedAug 26, 2022
Enrollment StartNov 7, 2022
Primary CompletionMar 31, 2025
Study CompletionJul 8, 2025
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 3.9 years ago
Interventions
Rimegepantdrug
Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
Placebodrug
Matching placebo with every other day dosing during DBT phase